Keppra 1000 mg (Levetiracetam)

Adult dose

The film-coated tablets and oral solution are administered orally and may be taken with or without food, with a sufficient amount of water. The daily dose is divided into 2 equal doses and administered twice daily. Monotherapy and adjunctive therapy for partial-onset seizures (adults and adolescents aged 18 years or older and weighing 50 kg or more): Initiate treatment with 500mg twice daily; if necessary, the dose may be reduced to 250mg twice daily. The dose may be increased to 500mg per dose after 2 weeks, and may be increased or decreased by 500mg or 1000mg per day every 2 to 4 weeks. The maximum recommended dose is 3000mg per day. Adjunctive therapy for primary generalized tonic-clonic seizures (adults and adolescents aged 18 years or older and weighing 50 kg or more): Initiate treatment with 500mg twice daily; if necessary, the dose may be reduced to 250mg twice daily. The dose may be increased to 500mg per dose after 2 weeks, and may be increased or decreased by 500mg or 1000mg per day every 2 weeks. The maximum recommended dose is 3000mg per day. Patients with renal impairment: Administer twice daily according to creatinine clearance, adjusting the dose to 500-1500mg (normal), 500-1000mg (mild), 250-750mg (moderate), or 250-500mg (severe). Patients with end-stage renal disease undergoing dialysis should receive 500-1000mg once daily. An initial loading dose of 750mg is recommended on the first day of treatment, followed by an additional 250-500mg after dialysis. Elderly patients (65 years or older): Dose adjustment according to reduced renal function is recommended.

Child dose

Monotherapy and adjunctive therapy for partial-onset seizures (children aged 4 years or older to 11 years, and adolescents aged 12 to 17 years weighing less than 50 kg): Initiate treatment with 10mg/kg twice daily. The dose may be increased up to 60mg/kg per day according to clinical response and tolerability; do not increase or decrease the dose by more than 20mg/kg per day every 2 weeks. For children weighing 20kg or less, it is recommended to initiate treatment with the 100mg/ml oral solution. For children weighing 20~40kg, initiate treatment with 250mg twice daily; the dose may be increased by 500mg per day every 2 weeks, up to a maximum of 1500mg per day. For children weighing more than 40kg, initiate treatment with 500mg twice daily; the dose may be increased by 1000mg per day every 2 weeks, up to a maximum of 3000mg per day. The dose for children weighing 50kg or more is the same as the adult dose. Adjunctive therapy for myoclonic seizures (children aged 12 years or older): Initiate treatment with 500mg twice daily; if necessary, the dose may be reduced to 250mg twice daily. The dose may be increased or decreased by 500mg or 1000mg per day every 2 weeks, up to a maximum of 3000mg per day. Adjunctive therapy for primary generalized tonic-clonic seizures (children aged 12 years or older and adolescents aged 12-17 years weighing less than 50 kg): Initiate treatment with 10mg/kg twice daily and increase the dose by 20mg/kg per day every 2 weeks, up to a maximum of 60mg/kg per day. Children with renal impairment and adolescents weighing less than 50 kg: Administer twice daily according to creatinine clearance; the dose is 10-30mg/kg (normal), 10-20mg/kg (mild), 5-15mg/kg (moderate), or 5-10mg/kg (severe). Patients with end-stage renal disease undergoing dialysis should receive 10-20mg/kg once daily. A loading dose of 15mg/kg on the first day, followed by an additional 5-10mg/kg after dialysis, is recommended. Oral formulations are not recommended for infants younger than 1 month. Tablets are not recommended for children 4 years or younger; the oral solution should be administered. Injection is not recommended for children younger than 16 years.

This medication is used in the treatment of epilepsy and may increase the risk of suicidal thoughts or behaviors; thus, patients and caregivers should carefully monitor for mood changes, depression, or unusual behavioral changes. This medication may affect the central nervous system, leading to symptoms such as drowsiness, fatigue, coordination difficulties, and behavioral abnormalities, particularly within the first four weeks of initial administration. Sudden discontinuation of this medication may exacerbate seizures, so the dosage should be gradually reduced as per the physician's instructions. Patients with a history of allergy or hypersensitivity to any component of this medication should not use it. Patients with suicidal thoughts or symptoms of depression should consult their physician, and dosage adjustment may be necessary for those with impaired kidney function. Blood-related adverse reactions such as decreased blood cell counts may occur, so regular blood tests are recommended if any unusual symptoms arise. This medication may induce psychiatric symptoms such as irritability and aggression, and if mood changes or behavioral abnormalities occur, consultation with a physician is advised. Seizures may worsen while taking this medication, so immediate consultation with healthcare professionals is required if seizure symptoms intensify. As this medication may affect heart function, caution is necessary for patients with heart disease or electrolyte imbalances. Common side effects include drowsiness, fatigue, headache, dizziness, behavioral changes, abdominal pain, diarrhea, and rash, and immediate medical attention should be sought if serious adverse reactions occur. Women who are pregnant or planning to become pregnant should consult their healthcare provider before taking this medication, and breastfeeding mothers should consider stopping either breastfeeding or the medication. Special caution is required when administering to children or the elderly, especially elderly patients with impaired kidney function, who should have their dosage adjusted carefully. Drowsiness or decreased concentration may occur during driving or operating machinery, so caution is advised. In cases of overdose, symptoms such as drowsiness, agitation, aggression, and decreased consciousness may appear, requiring immediate medical assistance and possibly blood dialysis. This medication generally has low drug interactions with other anti-epileptic drugs or oral contraceptives, but careful monitoring of blood levels is necessary when used concomitantly with methotrexate. Proper storage is crucial, and this medication should be kept out of reach of children.

• suicidal ideation
• suicidal behavior
• depression
• abnormal changes in mood and behavior
• drowsiness
• fatigue
• coordination movement disorder
• abnormal behavior
• lethargy
• behavioral disorders

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to preserve its efficacy for an extended period.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle